Larry L. Augsburger, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Larry L. Augsburger, PhD


Larry L. Augsburger, PhD, is a Pharmtech editorial advisory board (EAB) member

Larry L. Augsburger, PhD
Professor, Department of
Pharmaceutics
University of Maryland

Augsburger is an emeritus professor at the University of Maryland School of Pharmacy. He previously served as the Shangraw Professor of Industrial Pharmacy and Pharmaceutics, chair of the department of pharmaceutics and director of pharmaceutics graduate programs. He has overseen graduate and postdoctoral student research in the areas of design and optimization of immediate release and extended release oral solid dosage forms, the functionality of excipients, the instrumentation of pharmaceutical processing equipment, and botanical dietary supplement product development and quality.

Augsburger established the Drug Development Facility in the school of pharmacy, which later became UPM Pharmaceuticals, Inc., a university-affiliated for-profit firm for developing drugs and manufacturing clinical supplies. A founding father of UPM, he served for five years as its vice-president of pharmaceutical development and manufacture.

He was a principal investigator and directed the research programs of the $12-million University of Maryland-FDA Collaborative Agreements that led to the development of SUPAC regulatory policies for immediate- and modified-release oral solid dosage forms. Augsburger is an elected fellow and former president of the American Association of Pharmaceutical Scientists (AAPS). Among his awards are the Federation Internationale Pharmaceutique (FIP) Industrial Pharmacy medal, the FDA Commissioner's Special Citation, the AAPS Research Achievement Award and the AAPS Outstanding Educator Award.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here